Samsung Biologics Sustainability Profile
Samsung Biologics, a leading player in the biopharmaceutical industry, is headquartered in Incheon, South Korea (KR). Founded in 2011, the company has rapidly established itself as a key provider of contract development and manufacturing services (CDMO) for biopharmaceuticals, catering to a global clientele. With a focus on monoclonal antibodies and other biologics, Samsung Biologics offers unique solutions that leverage cutting-edge technology and state-of-the-art facilities. The company has achieved significant milestones, including the completion of its third manufacturing plant, which enhances its production capacity and reinforces its market position. Recognised for its commitment to quality and innovation, Samsung Biologics continues to set industry standards, making it a preferred partner for biopharmaceutical companies worldwide.
DitchCarbon Score
How does Samsung Biologics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Samsung Biologics's score of 48 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Samsung Biologics's reported carbon emissions
In 2023, Samsung Biologics reported total carbon emissions of approximately 754,473,000 kg CO2e. This figure includes 528,480,000 kg CO2e from Scope 1 emissions, 155,522,000 kg CO2e from Scope 2 emissions, and 528,480,000 kg CO2e from Scope 3 emissions. This represents a significant reduction from 2022, when total emissions were about 961,800,000 kg CO2e, with Scope 1 at 55,716,000 kg CO2e, Scope 2 at 114,372,000 kg CO2e, and Scope 3 at 791,713,000 kg CO2e. Samsung Biologics has set ambitious climate commitments, aiming for net zero emissions by 2050 or earlier. The company plans to reduce direct emissions by 32% by 2030 and 62% by 2040, using 2022 as the baseline year. Additionally, they aim to cut suppliers' emissions by 36% by 2030 and 73% by 2040. The emissions data is not cascaded from any parent organization, and all figures are reported directly by Samsung Biologics Co., Ltd. The company is actively working towards its climate goals, demonstrating a commitment to sustainability in the biopharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 41,469,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 |
| Scope 2 | 84,993,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Samsung Biologics's Industry?
How Carbon Intensive is Samsung Biologics's Location?
Samsung Biologics's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Samsung Biologics has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
